Wall Street brokerages predict that NewLink Genetics Corp (NASDAQ:NLNK) will post earnings per share of ($0.27) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for NewLink Genetics’ earnings. NewLink Genetics reported earnings of ($0.20) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 35%. The firm is scheduled to report its next quarterly earnings results on Thursday, November 7th.
On average, analysts expect that NewLink Genetics will report full year earnings of ($0.03) per share for the current fiscal year. For the next financial year, analysts forecast that the company will report earnings of ($1.08) per share. Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow NewLink Genetics.
NewLink Genetics (NASDAQ:NLNK) last released its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.02. The company had revenue of $0.15 million for the quarter. NewLink Genetics had a negative return on equity of 34.44% and a negative net margin of 6,587.56%.
A number of equities research analysts have recently weighed in on NLNK shares. Zacks Investment Research raised NewLink Genetics from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a report on Saturday, August 3rd. ValuEngine raised NewLink Genetics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.
A number of large investors have recently made changes to their positions in NLNK. Tower Research Capital LLC TRC raised its holdings in NewLink Genetics by 182.9% during the second quarter. Tower Research Capital LLC TRC now owns 20,317 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 13,136 shares in the last quarter. Pennsylvania Trust Co bought a new stake in NewLink Genetics during the first quarter worth approximately $48,000. Virtu Financial LLC bought a new stake in NewLink Genetics during the first quarter worth approximately $60,000. Two Sigma Advisers LP raised its holdings in NewLink Genetics by 22.6% during the fourth quarter. Two Sigma Advisers LP now owns 110,000 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 20,300 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in NewLink Genetics during the second quarter worth approximately $178,000. 33.72% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NLNK traded up $0.03 during mid-day trading on Friday, reaching $1.56. 203,800 shares of the company’s stock traded hands, compared to its average volume of 345,553. The business’s 50-day moving average price is $1.55 and its 200-day moving average price is $1.66. The stock has a market capitalization of $57.09 million, a P/E ratio of -1.08 and a beta of 1.32. The company has a debt-to-equity ratio of 0.08, a quick ratio of 13.33 and a current ratio of 12.77. NewLink Genetics has a 12 month low of $1.28 and a 12 month high of $3.21.
NewLink Genetics Company Profile
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.